Teva moves into top emerging market with Rimsa acquisition

JERUSALEM — Teva announced Thursday that it would be acquiring Mexican pharmaceutical manufacturer and distributor Representaciones e Investigaciones Médica SA (Rimsa). The $2.3 transaction will move Teva into Latin America’s second largest market and one of the world’s top emerging markets.

Rimsa, which had 2014 revenue of $227 million and has seen year-over-year growth of 10.6% every year since 2011 brings to Teva its portfolio of specialty products, which includes fixed-dose combination pharmaceuticals.

The acquisition, which will be covered by Teva’s cash on hand and lines of credit, is expected to close in the first quarter of 2016, and Teva expects it to be accretive to the company’s earnings by the first quarter of 2017.

“For 45 years, Rimsa has operated as a leading pharmaceutical company in Mexico, the second largest healthcare market in Latin America, with a high growth, unique and diversified business model,” Rimsa CEO Luis Jorge Pérez said. “We share Teva's focus on providing quality healthcare and we are excited to become a part of Teva in meeting the needs of a population of 120 million.”

NASP announces new leadership, establishes advisory council

ALEXANDRIA, Va. — The National Association of Specialty Pharmacy has been busy at its 2015 Annual Meeting & Expo. NASP on Thursday announced that it had elected new leadership, established advisory committees for stakeholders and unveiled its new Center for Specialty Pharmacy Education.

The organization’s board of directors has selected Burt Zweigenhaft as the next president, succeeding Mike Ellis in 2016. The board also elected Rebecca Shanahan as president-elect, to take over for Zweigenhaft in 2017. Zweigenhaft has worked for several years in oncology, working at Onco360 from 2005 until June 2015, and currently serves on the NASP board of directors’ executive committee.

“I look forward to the accomplishments that NASP will make in the year ahead," Ellis said. “Burt has been involved with NASP and dedicated to its mission since the beginning. Rebecca is a strong leader who was involved in SPAARx and the merger of the organizations to create a unified, influential organization for specialty pharmacy. They both bring proven leadership and industry knowledge to this organization.”

NASP also added Kelly Ratliff, COO of U.S. bioservices at AmerisourceBergen Specialty Group, and Mark Vineis, VP of Cardinal Health Specialty Pharmacy, to the board of directors for 2016.

In addition to elections, NASP has also established five new Advisory Councils that are meant to serve specialty pharmacy stakeholders: specialty pharmacy providers, pharmaceutical/biotechnology manufacturers, managed care organizations, institutional pharmacy and GPOs and distributors. The organization said it would put out a call for volunteers in November, with the board of directors making final appointments. The councils will review proposes public policy, comment on NASP programs and services and assist the board in choosing the organization’s strategic direction.

“The establishment of Advisory Councils gives a formal voice to all NASP stakeholders with regard to membership, policy, education, and other NASP activities," Ellis said. "We will be encouraging members to serve on an Advisory Council and by doing so take a more active role in the progress of NASP and advocacy for the specialty pharmacy industry.

In addition to providing more opportunities for stakeholders to have a say in the organization’s direction, NASP is also looking to ensure members’ educational needs are taken care of, launching its Center for Specialty Pharmacy Education. The CSPE, made possible by a partnership with ProCE to offer specialty pharmacy education to pharmacists and other health care professionals.

“Education is a fundamental component of NASP's vison,” executive director Jim Smeeding said. “We intend to offer premier, educational opportunities to our members and others in our industry in a manner that is convenient and accessible for them.”

Over the next several months, NASP will roll out dozens of CE offerings, including webinars and home study, the organization said.

RELATED NEWS

The Food and Drug Administration has approved a generic of Hoffman-La Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.
The product is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older, as well as to prevent influenza A and B in patients 1 year old and older. The drug had U.S. sales of roughly $467.8 million for the 12 months ended October 2017, according to IQVIA data.

Behavioral health pharmacy and telepsychiatry company Genoa, a QoL Healthcare Company, has reached a big number with its remote psychiatry offering. The Tukwila, Wash.-based company announced Tuesday that it had facilitated more than 100,000 telepsych consultations on its video conferencing platform.
Genoa attributes the milestone to its recent buildup of its telepsychiatry operations, which grew to include 35 in 2017 from 20 at the start of the year, and included 250 providers. In 2017, the company grew to serve more than 2,500 patients per week.

This year's flu continues to be Texas big, according to the Walgreens Flu Index released Wednesday, as the top 10 communities experiencing the greatest amount of flu incidence were all located in the Lone Star State for the week ended Jan. 6.
Iowa, Idaho and Arkansas rank behind Texas in terms of flu activity. And Montana, Idaho and Iowa ranked highest among states experiencing flu activity gains.

Amneal Biosciences has launched its generic of Otsuka’s Busulfex (busulfan injection, 6 mg/ml). The product is indicated to treat chronic myelogenous leukemia.
Amneal said that its generic is available in cartons of eight single-dose vials, each of which contains 60 mg of the drug in a 10-ml clear sterile solution. The product is made without natural rubber, latex, gluten or preservatives, Amneal said.
The drug had U.S. sales of roughly $80 million for the 12 months ended October 2017, according to data from IQVIA.

Amneal Pharmaceuticals has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. This generic from the Bridgewater, N.J.-based company is an AB-rated therapeutic equivalent to Renvela.
Amneal also launched five other products in addition to sevelamer carbonate:

Forgotten Password

Registration complete

REGISTER

USERNAME *

Spaces are allowed; punctuation is not allowed except for periods, hyphens, and underscores.

E-MAIL ADDRESS *

A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.

Password *

Confirm Password *

Please choose a password for your account; it must be 8 - 30 characters. .

First Name *

Last Name *

Company Name *

Job Title *

ZIP *

Are you a *

Retailer or Healthcare professional

Non-Retailer

How many stores do you operate?: *

Which best describes the business/industry you work in?: *

Which best describes your job title?: *

Please select the newsletters you would like to subscribe to

DSN A.M.
Daily news stories covering the retail drug industry

Breaking News
First-to-the-market with developing stories in the industry